ELIZABETH EGGEBRECHT: Open Payments
NPI 1174038590 · COLUMBIA, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,094 in 238 payments from 11 companies in 2025. Trend: 2023 $2,065 · 2024 $2,022 · 2025 $3,094
Food & beverage: $3,094
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 41 | $536 |
| Teva Pharmaceuticals USA, Inc. | 69 | $498 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 28 | $462 |
| Alkermes, Inc. | 28 | $438 |
| Janssen Pharmaceuticals, Inc | 16 | $384 |
| Otsuka America Pharmaceutical, Inc. | 21 | $330 |
| E.R. Squibb & Sons, L.L.C. | 15 | $248 |
| ABBVIE INC. | 17 | $142 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
Products named: INGREZZA, CAPLYTA, ARISTADA, INVEGA SUSTENNA, AUSTEDO XR, COBENFY, UZEDY, ABILIFY MAINTENA.
Industry payments across SC — which companies pay providers there.
